U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination
  • The following terms were not found in MedGen: comsmall, Cyrillicss.

Grade 3 Ejection Fraction Decreased, CTCAE

MedGen UID:
1633200
•Concept ID:
C4686174
•
Finding

Definition

Resting ejection fraction (EF) 39-20%; >=20% drop from baseline [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVGrade 3 Ejection Fraction Decreased, CTCAE

Recent clinical studies

Etiology

Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies.
Shalabi H, Sachdev V, Kulshreshtha A, Cohen JW, Yates B, Rosing DR, Sidenko S, Delbrook C, Mackall C, Wiley B, Lee DW, Shah NN
J Immunother Cancer 2020 Sep;8(2) doi: 10.1136/jitc-2020-001159. PMID: 32883871Free PMC Article
Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients.
Vulsteke C, Pfeil AM, Maggen C, Schwenkglenks M, Pettengell R, Szucs TD, Lambrechts D, Dieudonné AS, Hatse S, Neven P, Paridaens R, Wildiers H
Breast Cancer Res Treat 2015 Jul;152(1):67-76. Epub 2015 May 28 doi: 10.1007/s10549-015-3437-9. PMID: 26017071
Cutaneous and cardiac toxicity of concurrent trastuzumab and adjuvant breast radiotherapy: a single institution series.
Meattini I, Cecchini S, Muntoni C, Scotti V, De Luca Cardillo C, Mangoni M, Bonomo P, Nori J, Casella D, Simoncini R, Orzalesi L, Bianchi S, Livi L
Med Oncol 2014 Apr;31(4):891. Epub 2014 Feb 18 doi: 10.1007/s12032-014-0891-x. PMID: 24535610

Diagnosis

Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients.
Vulsteke C, Pfeil AM, Maggen C, Schwenkglenks M, Pettengell R, Szucs TD, Lambrechts D, Dieudonné AS, Hatse S, Neven P, Paridaens R, Wildiers H
Breast Cancer Res Treat 2015 Jul;152(1):67-76. Epub 2015 May 28 doi: 10.1007/s10549-015-3437-9. PMID: 26017071

Therapy

Adjuvant Trastuzumab Emtansine (T-DM1) and Concurrent Radiotherapy for Residual Invasive HER2-positive Breast Cancer: Single-center Preliminary Results.
Zolcsák Z, Loirat D, Fourquet A, Kirova YM
Am J Clin Oncol 2020 Dec 1;43(12):895-901. doi: 10.1097/COC.0000000000000769. PMID: 33027084
Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies.
Shalabi H, Sachdev V, Kulshreshtha A, Cohen JW, Yates B, Rosing DR, Sidenko S, Delbrook C, Mackall C, Wiley B, Lee DW, Shah NN
J Immunother Cancer 2020 Sep;8(2) doi: 10.1136/jitc-2020-001159. PMID: 32883871Free PMC Article
A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer.
Curigliano G, Romieu G, Campone M, Dorval T, Duck L, Canon JL, Roemer-Becuwe C, Roselli M, Neciosup S, Burny W, Callegaro A, de Sousa Alves PM, Louahed J, Brichard V, Lehmann FF
Breast Cancer Res Treat 2016 Apr;156(2):301-10. Epub 2016 Mar 14 doi: 10.1007/s10549-016-3750-y. PMID: 26975189
Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients.
Vulsteke C, Pfeil AM, Maggen C, Schwenkglenks M, Pettengell R, Szucs TD, Lambrechts D, Dieudonné AS, Hatse S, Neven P, Paridaens R, Wildiers H
Breast Cancer Res Treat 2015 Jul;152(1):67-76. Epub 2015 May 28 doi: 10.1007/s10549-015-3437-9. PMID: 26017071
Cutaneous and cardiac toxicity of concurrent trastuzumab and adjuvant breast radiotherapy: a single institution series.
Meattini I, Cecchini S, Muntoni C, Scotti V, De Luca Cardillo C, Mangoni M, Bonomo P, Nori J, Casella D, Simoncini R, Orzalesi L, Bianchi S, Livi L
Med Oncol 2014 Apr;31(4):891. Epub 2014 Feb 18 doi: 10.1007/s12032-014-0891-x. PMID: 24535610

Prognosis

Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients.
Vulsteke C, Pfeil AM, Maggen C, Schwenkglenks M, Pettengell R, Szucs TD, Lambrechts D, Dieudonné AS, Hatse S, Neven P, Paridaens R, Wildiers H
Breast Cancer Res Treat 2015 Jul;152(1):67-76. Epub 2015 May 28 doi: 10.1007/s10549-015-3437-9. PMID: 26017071
Cutaneous and cardiac toxicity of concurrent trastuzumab and adjuvant breast radiotherapy: a single institution series.
Meattini I, Cecchini S, Muntoni C, Scotti V, De Luca Cardillo C, Mangoni M, Bonomo P, Nori J, Casella D, Simoncini R, Orzalesi L, Bianchi S, Livi L
Med Oncol 2014 Apr;31(4):891. Epub 2014 Feb 18 doi: 10.1007/s12032-014-0891-x. PMID: 24535610

Clinical prediction guides

Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies.
Shalabi H, Sachdev V, Kulshreshtha A, Cohen JW, Yates B, Rosing DR, Sidenko S, Delbrook C, Mackall C, Wiley B, Lee DW, Shah NN
J Immunother Cancer 2020 Sep;8(2) doi: 10.1136/jitc-2020-001159. PMID: 32883871Free PMC Article
A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer.
Curigliano G, Romieu G, Campone M, Dorval T, Duck L, Canon JL, Roemer-Becuwe C, Roselli M, Neciosup S, Burny W, Callegaro A, de Sousa Alves PM, Louahed J, Brichard V, Lehmann FF
Breast Cancer Res Treat 2016 Apr;156(2):301-10. Epub 2016 Mar 14 doi: 10.1007/s10549-016-3750-y. PMID: 26975189
Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients.
Vulsteke C, Pfeil AM, Maggen C, Schwenkglenks M, Pettengell R, Szucs TD, Lambrechts D, Dieudonné AS, Hatse S, Neven P, Paridaens R, Wildiers H
Breast Cancer Res Treat 2015 Jul;152(1):67-76. Epub 2015 May 28 doi: 10.1007/s10549-015-3437-9. PMID: 26017071

Supplemental Content

Table of contents

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...